Table 3.
The clinical parameters of matched LAT and non-LAT groups.
| LAT (n = 215) | Non-LAT (n = 215) | P | ||
|---|---|---|---|---|
| Age | ||||
| Median (range) | 64 (39–91) | 64 (41–88) | 64 (39–91) | |
| <70 | 352 | 176 | 176 | 1.000 |
| ≥70 | 78 | 39 | 39 | |
| Gender | ||||
| Male | 328 | 166 | 162 | 0.650 |
| Female | 102 | 49 | 53 | |
| Race | ||||
| White | 272 | 139 | 133 | 0.335 |
| Black | 108 | 48 | 60 | |
| Others | 50 | 28 | 22 | |
| T | ||||
| T1–2 | 308 | 157 | 151 | 0.521 |
| T3–4 | 122 | 58 | 64 | |
| N | ||||
| N0 | 126 | 64 | 62 | 0.832 |
| N+ | 304 | 151 | 153 | |
| Metastases at diagnosis | ||||
| Bone metastases | 87 | 42 | 45 | 0.719 |
| No bone metastases | 343 | 173 | 170 | |
| Brain metastases | 2 | 1 | 1 | 1.000 |
| No brain metastases | 428 | 214 | 214 | |
| Liver metastases | 201 | 99 | 102 | 0.772 |
| No liver metastases | 229 | 116 | 113 | |
| Lung metastases | 151 | 73 | 78 | 0.613 |
| No lung metastases | 279 | 142 | 137 | |